According to a new report, published by KBV research, The Global Androgenetic Alopecia Market size is expected to reach $4.6 billion by 2030, rising at a market growth of 8.1% CAGR during the forecast period.
The Pharmaceuticals segment is leading the Global Androgenetic Alopecia Market, By Treatment in 2022; thereby, achieving a market value of $4.4 Billion by 2030. Pharmaceutical treatments, especially topical solutions, and oral medications offer convenient options for patients. For example, as per the data from the International Trade Administration, Belgium’s pharmaceutical industry spends $1.64 billion (€1.5 billion) on R&D every year, which is equivalent to 40 percent of all private investment made in Belgium. As a result, Belgium is home to 29 of the world’s top 30 pharmaceutical companies, including important subsidiaries of major U.S. companies such as Johnson and Johnson and Pfizer.
The Female segment is registering a CAGR of 8.9% during (2023 - 2030). Increase awareness about female pattern hair loss through educational campaigns. These initiatives focus on the prevalence of androgenetic alopecia in women, its causes, and the available treatment options. Dispelling myths and reducing the stigma associated with hair loss can encourage women to seek help.
The Prescriptions segment is generating the highest revenue in the Global Androgenetic Alopecia Market, By Sales Channel in 2022; thereby, achieving a market value of $2.9 Billion by 2030. Growing prescriptions are often linked to increased awareness among patients about available treatments for androgenetic alopecia. Healthcare professionals, particularly dermatologists, play a central role in prescribing medications for androgenetic alopecia. For example, according to a report published by the Centers for Disease Control and Prevention, between July and August of 2019, approximately 7 in 10 adults in the 40–79 age range used at least 1 prescription drug in both the US and Canada (69.0% and 65.5%, respectively) and approximately 1 in 5 used at least 5 prescription drugs (22.4% in the US and 18.8% in Canada).
The Homecare Settings segment is experiencing a CAGR of 8.6% during (2023 - 2030). Homecare settings allow individuals to use topical treatments, including minoxidil solutions or foams, as part of their daily routines. Additionally, specialized shampoos that promote hair health and reduce hair loss can be easily incorporated into homecare regimens. Prescription oral medications like finasteride, which are commonly used for androgenetic alopecia, can be taken at home. The convenience of oral medications facilitates patient adherence to treatment plans, contributing to the overall effectiveness of pharmaceutical interventions.
Full Report: https://www.kbvresearch.com/androgenetic-alopecia-market/
The North America region dominated the Global Androgenetic Alopecia Market, By Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.6 Billion by 2030. The Europe region is anticipating a CAGR of 7.9% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 9% during (2023 - 2030).
By Treatment
By Gender
By Sales Channel
By End-use
By Geography
Unique Offerings 
